

Wei-jin Huang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4429207/wei-jin-huang-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

6,648
citations

32
h-index

80
g-index

151
ext. papers

10,793
ext. citations

15.6
avg, IF

6.06
L-index

#	Paper	IF	Citations
137	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.. <i>Cell Research</i> , 2022 ,	24.7	10
136	A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants.. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7, 23	21	0
135	Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal.. <i>Archives of Virology</i> , 2022 , 167, 459	2.6	
134	Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants.. <i>Nature</i> , 2022 ,	50.4	26
133	The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain.. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7, 18	21	2
132	Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift.. <i>Journal of Medical Virology</i> , 2022 ,	19.7	2
131	Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2.. <i>Cell Discovery</i> , 2022 , 8, 17	22.3	2
130	Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.. <i>Emerging Microbes and Infections</i> , 2022 , 1-26	18.9	4
129	Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates.. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7, 69	21	2
128	Circular RNA vaccines against SARS-CoV-2 and emerging variants.. <i>Cell</i> , 2022 ,	56.2	21
127	TIM-1 Augments Cellular Entry of Ebola Virus Species and Mutants, Which Is Blocked by Recombinant TIM-1 Protein.. <i>Microbiology Spectrum</i> , 2022 , e0221221	8.9	0
126	Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD.. <i>MedComm</i> , 2022 , 3, e130	2.2	3
125	Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.. <i>European Journal of Medicinal Chemistry</i> , 2022 , 234, 114209	6.8	0
124	Analysis of SARS-CoV-2 Variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity.. <i>Emerging Microbes and Infections</i> , 2022 , 1-32	18.9	0
123	Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma.. <i>Advanced Science</i> , 2022 , e2104333	13.6	1
122	Screening and Identification of HTNV Entry Inhibitors with High-throughput Pseudovirus-based Chemiluminescence.. <i>Virologica Sinica</i> , 2022 ,	6.4	1
121	Analysis of the evolution, infectivity and antigenicity of circulating rabies virus strains.. <i>Emerging Microbes and Infections</i> , 2022 , 1-30	18.9	2

120	ACE2 Decoy Receptor Generated by High-throughput Saturation Mutagenesis Efficiently Neutralizes SARS-CoV-2 and Its Prevalent Variants.. <i>Emerging Microbes and Infections</i> , 2022 , 1-0	18.9	0
119	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.. <i>Nature</i> , 2021 ,	50.4	249
118	The significant immune escape of pseudotyped SARS-CoV-2 Variant Omicron. <i>Emerging Microbes and Infections</i> , 2021 , 1-11	18.9	102
117	Immunogenicity and Safety of a Three-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial.. <i>Journal of Infectious Diseases</i> , 2021 ,	7	1
116	Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. <i>Emerging Microbes and Infections</i> , 2021 , 1-30	18.9	7
115	A second functional furin site in the SARS-CoV-2 spike protein. <i>Emerging Microbes and Infections</i> , 2021 , 1-35	18.9	3
114	Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 346	21	10
113	Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice. <i>Cell Discovery</i> , 2021 , 7, 91	22.3	4
112	Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization. <i>Communications Biology</i> , 2021 , 4, 1196	6.7	16
111	Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2. <i>National Science Review</i> , 2021 , 8, nwa297	10.8	14
110	Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 134	21	106
109	S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. <i>Nature Communications</i> , 2021 , 12, 1346	17.4	65
108	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. <i>Cell</i> , 2021 , 184, 2362-2371	36.2e9	197
107	Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. <i>Chinese Medical Journal</i> , 2021 , 134, 1289-1298	2.9	29
106	Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses. <i>Cell Discovery</i> , 2021 , 7, 21	22.3	8
105	Cellular tropism and antigenicity of mink-derived SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 196	21	4
104	Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. <i>Cell Research</i> , 2021 , 31, 732-741	24.7	47
103	The first Chinese national standards for SARS-CoV-2 neutralizing antibody. <i>Vaccine</i> , 2021 , 39, 3724-3730	4.1	3

102	Methods to Identify Immunogenic Peptides in SARS-CoV-2 Spike and Protective Monoclonal Antibodies in COVID-19 Patients. <i>Small Methods</i> , 2021 , 5, 2100058	12.8	2
101	The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. <i>Frontiers in Immunology</i> , 2021 , 12, 687869	8.4	9
100	Monitoring Neutralization Property Change of Evolving Hantaan and Seoul Viruses with a Novel Pseudovirus-Based Assay. <i>Virologica Sinica</i> , 2021 , 36, 104-112	6.4	6
99	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, 39-51	25.5	480
98	Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. <i>Nature Microbiology</i> , 2021 , 6, 51-58	26.6	53
97	Simultaneous determination of capsid proteins in nine-valent human papilloma virus vaccines by liquid chromatography tandem mass spectrometry. <i>Journal of Separation Science</i> , 2021 , 44, 557-564	3.4	1
96	Lentil lectin derived from exhibit broad antiviral activities against SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2021 , 10, 1519-1529	18.9	10
95	Clofazimine: A Promising Inhibitor of Rabies Virus. <i>Frontiers in Pharmacology</i> , 2021 , 12, 598241	5.6	2
94	The molecular basis for SARS-CoV-2 binding to dog ACE2. <i>Nature Communications</i> , 2021 , 12, 4195	17.4	17
93	Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants. <i>Cell Discovery</i> , 2021 , 7, 53	22.3	6
92	Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. <i>Nature Communications</i> , 2021 , 12, 4210	17.4	23
91	A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021 , 12, 5000	17.4	7
90	Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants. <i>Cell Research</i> , 2021 , 31, 1130-1133	24.7	18
89	Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. <i>Lancet Infectious Diseases, The</i> , 2021 ,	25.5	45
88	Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19. <i>Vaccine</i> , 2021 , 39, 6050-6056	4.1	0
87	Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. <i>Antiviral Research</i> , 2021 , 194, 105161	10.8	1
86	Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage. <i>Bioorganic Chemistry</i> , 2021 , 115, 105196	5.1	1
85	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. <i>Emerging Microbes and Infections</i> , 2021 , 10, 1574-1588	18.9	3

84	Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. <i>Emerging Microbes and Infections</i> , 2021 , 10, 1390-1403	18.9	8
83	High-Throughput Screening and Identification of Human Adenovirus Type 5 Inhibitors.. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 767578	5.9	
82	A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. <i>Cell Host and Microbe</i> , 2020 , 28, 124-133.e4	23.4	348
81	High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. <i>Journal of Infection</i> , 2020 , 81, 420-426	18.9	133
80	Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2020 , 9, 680-686	18.9	418
79	Simultaneous quantification of major capsid protein of human papillomavirus 16 and human papillomavirus 18 in multivalent human papillomavirus vaccines by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2020 , 1619, 460962	4.5	2
78	In Vivo Bioluminescent Imaging of Marburg Virus in a Rodent Model. <i>Methods in Molecular Biology</i> , 2020 , 2081, 177-190	1.4	2
77	Screening and Identification of Marburg Virus Entry Inhibitors Using Approved Drugs. <i>Virologica Sinica</i> , 2020 , 35, 235-239	6.4	4
76	HIV-1 pseudoviruses constructed in China regulatory laboratory. <i>Emerging Microbes and Infections</i> , 2020 , 9, 32-41	18.9	5
75	Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. <i>Nature Protocols</i> , 2020 , 15, 3699-3715	18.8	113
74	A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. <i>Nature</i> , 2020 , 586, 572-577	50.4	348
73	Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. <i>Frontiers of Medicine</i> , 2020 , 14, 746-751	12	42
72	The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. <i>Cell</i> , 2020 , 182, 1284-1294.e8	50.2	399
71	Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. <i>Nature Communications</i> , 2020 , 11, 5752	17.4	40
70	A Thermostable mRNA Vaccine against COVID-19. <i>Cell</i> , 2020 , 182, 1271-1283.e16	56.2	255
69	Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. <i>Science</i> , 2020 , 369, 1505-1509	33.3	232
68	A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. <i>Nature</i> , 2020 , 584, 120-124	52.4	844
67	Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs. <i>Npj Vaccines</i> , 2020 , 5, 89	9.5	1

66	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. <i>Cell</i> , 2020 , 183, 1013-1023.e13	56.2	145
65	Absence of hepatitis E virus RNA in semen samples of infertile male in China. <i>Gut</i> , 2020 , 69, 1363-1364	19.2	7
64	and efficacy of a Rift Valley fever virus vaccine based on pseudovirus. <i>Human Vaccines and Immunotherapeutics</i> , 2019 , 15, 2286-2294	4.4	13
63	Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities. <i>Emerging Microbes and Infections</i> , 2019 , 8, 272-281	18.9	10
62	Antigenic Drift of Influenza A(H7N9) Virus Hemagglutinin. <i>Journal of Infectious Diseases</i> , 2019 , 219, 19-25		20
61	Screening and evaluation of potential inhibitors against vaccinia virus from 767 approved drugs. <i>Journal of Medical Virology</i> , 2019 , 91, 2016-2024	19.7	2
60	Antigenic variations of recent street rabies virus. <i>Emerging Microbes and Infections</i> , 2019 , 8, 1584-1592	18.9	8
59	Detection of Hepatitis E Virus in Raw Pork and Pig Viscera As Food in Hebei Province of China. <i>Foodborne Pathogens and Disease</i> , 2019 , 16, 325-330	3.8	6
58	Hepatitis E virus was not detected in feces and milk of cows in Hebei province of China: No evidence for HEV prevalence in cows. <i>International Journal of Food Microbiology</i> , 2019 , 291, 5-9	5.8	9
57	Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells. <i>Human Vaccines and Immunotherapeutics</i> , 2018 , 14, 199-208	4.4	16
56	A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. <i>Viruses</i> , 2018 , 10,	6.2	35
55	Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/BTenv molecular clones derived from infections in China. <i>Emerging Microbes and Infections</i> , 2018 , 7, 90	18.9	2
54	Current status on the development of pseudoviruses for enveloped viruses. <i>Reviews in Medical Virology</i> , 2018 , 28, e1963	11.7	70
53	Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. <i>Scientific Reports</i> , 2017 , 7, 42769	4.9	37
52	Systematic identification of hepatitis E virus ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF- κ B pathway. <i>Virus Research</i> , 2017 , 228, 102-108	6.4	12
51	Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging. <i>Scientific Reports</i> , 2017 , 7, 3597	4.9	6
50	A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system. <i>Human Vaccines and Immunotherapeutics</i> , 2017 , 13, 1811-1817	4.4	26
49	Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. <i>Scientific Reports</i> , 2017 , 7, 45552	4.9	59

48	Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system. <i>Vaccine</i> , 2017 , 35, 6387-6394	4.1	12
47	An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions. <i>Vaccine</i> , 2017 , 35, 5172-5178	4.1	17
46	Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization. <i>Journal of Infectious Diseases</i> , 2017 , 216, 867-876	7	12
45	Detection and assessment of infectivity of hepatitis E virus in urine. <i>Journal of Hepatology</i> , 2016 , 64, 37-43	13.4	94
44	Expression and characterization of hepatitis E virus-like particles and non-virus-like particles from insect cells. <i>Biotechnology and Applied Biochemistry</i> , 2016 , 63, 362-70	2.8	6
43	Regulation and quality evaluation system for HIV diagnostics in China. <i>Biologicals</i> , 2016 , 44, 111-6	1.8	0
42	Effect of the maturation of neutralizing antibodies on human immunodeficiency virus (HIV) envelope evolution in HIV-infected subjects. <i>Infection, Genetics and Evolution</i> , 2016 , 38, 82-89	4.5	6
41	Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus. <i>Viruses</i> , 2016 , 8, 107	6.2	15
40	Multiple human papillomavirus infections and type-competition in women from a clinic attendee population in China. <i>Journal of Medical Virology</i> , 2016 , 88, 1989-98	19.7	1
39	Asialoglycoprotein receptor facilitates infection of PLC/PRF/5 cells by HEV through interaction with ORF2. <i>Journal of Medical Virology</i> , 2016 , 88, 2186-2195	19.7	19
38	Bioluminescent imaging of vaccinia virus infection in immunocompetent and immunodeficient rats as a model for human smallpox. <i>Scientific Reports</i> , 2015 , 5, 11397	4.9	14
37	Hepatitis E Virus Produced from Cell Culture Has a Lipid Envelope. <i>PLoS ONE</i> , 2015 , 10, e0132503	3.7	36
36	Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirions. <i>Journal of Medical Virology</i> , 2014 , 86, 1542-53	19.7	10
35	Comparison of the replication characteristics of vaccinia virus strains Guang 9 and Tian Tan in vivo and in vitro. <i>Archives of Virology</i> , 2014 , 159, 2587-96	2.6	16
34	Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12. <i>Virologica Sinica</i> , 2014 , 29, 299-307	6.4	5
33	Hepatitis E genotype 4 virus from feces of monkeys infected experimentally can be cultured in PLC/PRF/5 cells and upregulate host interferon-inducible genes. <i>Journal of Medical Virology</i> , 2014 , 86, 1736-44	19.7	19
32	Persistent hepatitis e virus genotype 4 infection in a child with acute lymphoblastic leukemia. <i>Hepatitis Monthly</i> , 2014 , 14, e15618	1.8	71
31	Analysis of the complete genome sequences of one swine and two human hepatitis E virus genotype 4 strains isolated in Beijing, China. <i>Infection, Genetics and Evolution</i> , 2013 , 18, 42-7	4.5	6

30	Comparison of hepatitis E virus genotypes from rabbits and pigs in the same geographic area: no evidence of natural cross-species transmission between the two animals. <i>Infection, Genetics and Evolution</i> , 2013 , 13, 304-9	4.5	17
29	Identification of a novel DRB1 allele through intergenic recombination between HLA-DRB1 and HLA-DRB3*02 in a Chinese family. <i>Human Immunology</i> , 2013 , 74, 1603-9	2.3	8
28	The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector. <i>Journal of Medical Virology</i> , 2013 , 85, 1550-6	19.7	14
27	Virus host protein interaction network analysis reveals that the HEV ORF3 protein may interrupt the blood coagulation process. <i>PLoS ONE</i> , 2013 , 8, e56320	3.7	22
26	A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China. <i>PLoS ONE</i> , 2012 , 7, e33392	3.7	19
25	Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China. <i>PLoS ONE</i> , 2012 , 7, e37532	3.7	5
24	Comparison on virulence and immunogenicity of two recombinant vaccinia vaccines, Tian Tan and Guang9 strains, expressing the HIV-1 envelope gene. <i>PLoS ONE</i> , 2012 , 7, e48343	3.7	9
23	Hepatitis E virus ORF3 antigens derived from genotype 1 and 4 viruses are detected with varying efficiencies by an anti-HEV enzyme immunoassay. <i>Journal of Medical Virology</i> , 2011 , 83, 827-32	19.7	12
22	INNO-LiPA HBV genotyping is highly consistent with direct sequencing and sensitive in detecting B/C mixed genotype infection in Chinese chronic hepatitis B patients and asymptomatic HBV carriers. <i>Clinica Chimica Acta</i> , 2010 , 411, 1951-6	6.2	8
21	Varying abilities of recombinant polypeptides from different regions of hepatitis E virus ORF2 and ORF3 to detect anti-HEV immunoglobulin M. <i>Journal of Medical Virology</i> , 2009 , 81, 1052-61	19.7	25
20	Cross-protection of hepatitis E virus genotypes 1 and 4 in rhesus macaques. <i>Journal of Medical Virology</i> , 2008 , 80, 824-32	19.7	46
19	Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E. <i>Journal of Medical Virology</i> , 2006 , 78, 1441-8	19.7	66
18	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies		30
17	Comprehensive Epitope Mapping of Broad Sarbecovirus Neutralizing Antibodies		1
16	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. <i>Nature</i> ,	50.4	37
15	B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes		4
14	Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 individuals		2
13	The Impact of Natural and Glycosylation Mutations in the SARS-CoV-2 Spike Protein on Viral Infectivity and Antigenicity. <i>SSRN Electronic Journal</i> ,	1	3

12	Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody	2
11	An antibody-dependent enhancement (ADE) activity eliminated neutralizing antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys	5
10	S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates	14
9	Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development	4
8	Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2	3
7	Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials	3
6	Heterologous vaccination strategy for containing COVID-19 pandemic	3
5	Structure and computation-guided design of a mutation-integrated trimeric RBD candidate vaccine with broad neutralization against SARS-CoV-2	1
4	A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2	19
3	A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron	1
2	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection	9
1	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. <i>Nature</i> ,	50.4 85